Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?

Nabil F. Saba; William M. Mendenhall; Kate Hutcheson; Carlos Suárez; Greg Wolf; Alfio Ferlito

doi:10.1002/cncr.31717

Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?

Nabil F. Saba, William M. Mendenhall, Kate Hutcheson, Carlos Suárez, Greg Wolf, Alfio Ferlito

Head & Neck Surgery

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	4163-4164
Number of pages	2
Journal	Cancer
Volume	124
Issue number	21
DOIs	https://doi.org/10.1002/cncr.31717
State	Published - Nov 1 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.31717

Cite this

@article{ff744176cb304b84b222222471aafb13,

title = "Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?",

author = "Saba, {Nabil F.} and Mendenhall, {William M.} and Kate Hutcheson and Carlos Su{\'a}rez and Greg Wolf and Alfio Ferlito",

note = "Funding Information: Nabil F. Saba reports participation in advisory boards for Bristol-Myers Squibb, Merck, Pfizer, Lilly, and Aduro. Kate Hutcheson reports grants from the Patient-Centered Outcomes Research Institute, the MD Anderson Institutional Research Grant Program, the National Cancer Institute, the National Institute for Dental and Craniofacial Research, and the National Institutes of Health (Cancer Center Support Grant) outside the submitted work. Greg Wolf reports personal fees from Merck, grants from IRX Therapeutics, and personal fees from Regeneron outside the submitted work.",

year = "2018",

month = nov,

day = "1",

doi = "10.1002/cncr.31717",

language = "English (US)",

volume = "124",

pages = "4163--4164",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "21",

}

TY - JOUR

T1 - Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy

T2 - Is it time to clarify our guidelines?

AU - Saba, Nabil F.

AU - Mendenhall, William M.

AU - Hutcheson, Kate

AU - Suárez, Carlos

AU - Wolf, Greg

AU - Ferlito, Alfio

N1 - Funding Information: Nabil F. Saba reports participation in advisory boards for Bristol-Myers Squibb, Merck, Pfizer, Lilly, and Aduro. Kate Hutcheson reports grants from the Patient-Centered Outcomes Research Institute, the MD Anderson Institutional Research Grant Program, the National Cancer Institute, the National Institute for Dental and Craniofacial Research, and the National Institutes of Health (Cancer Center Support Grant) outside the submitted work. Greg Wolf reports personal fees from Merck, grants from IRX Therapeutics, and personal fees from Regeneron outside the submitted work.

PY - 2018/11/1

Y1 - 2018/11/1

UR - http://www.scopus.com/inward/record.url?scp=85054500834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054500834&partnerID=8YFLogxK

U2 - 10.1002/cncr.31717

DO - 10.1002/cncr.31717

M3 - Comment/debate

C2 - 30289965

AN - SCOPUS:85054500834

SN - 0008-543X

VL - 124

SP - 4163

EP - 4164

JO - Cancer

JF - Cancer

IS - 21

ER -

Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this